TherapyTherapyТерапия2412-40362713-1823Bionika Media64656510.18565/therapy.2024.9.118-129REVIEWSОБЗОРЫResearch ArticleBronchial asthma with fixed respiratory obstruction: The problem and ways of its solutionБронхиальная астма с фиксированной обструкцией дыхательных путей: проблема и способы ее решенияhttps://orcid.org/0000-0002-7464-826XKaroliNina A.КаролиНина Анатольевна
Russian Federation

MD, Dr. Sci. (Medicine), professor of the Department of hospital therapy of the Faculty of general medicine

д. м. н., профессор кафедры госпитальной терапии лечебного факультета

nina.karoli.73@gmail.comhttps://orcid.org/0000-0002-3765-4812SazhnovaSvetlana I.СажноваСветлана Игоревна
Russian Federation

MD, PhD (Medicine), associate professor of the Department of hospital therapy of the Faculty of general medicine

к. м. н., доцент кафедры госпитальной терапии лечебного факультета

sazhnova.svetlana@mail.ruV.I. Razumovsky Saratov State Medical University of the Ministry of Healthcare of RussiaФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России281120241091181292301202523012025Copyright ©; 2024, Bionika MediaCopyright ©; 2024, ООО «Бионика Медиа»2024Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2412-4036/article/view/646565

Bronchial asthma (BA) is a chronic inflammatory disease of the respiratory tract with various phenotypes. Phenotype associated with a severe, difficult-to-control course of the disease is BA with fixed respiratory obstruction (FRO). The high risk of exacerbations, difficulty in achieving control and the severity of asthma in such kind of patients are occurring due to damage of the peripheral airways. In this regard, the main therapeutic target for this disease is the distal parts of bronchial tree, and the efficacy of inhalation therapy depends on the degree of drug deposition in them. Extrafine fixed combination of beclomethasone dipropionate, formoterol and glycopyrronium bromide affects inflammation in the distal bronchial tree and is of priority in the treatment of patients with severe bronchial asthma and FRO helping to achieve disease control.

Бронхиальная астма (БА) – хроническое воспалительное заболевание дыхательных путей, имеющее разнообразные фенотипы. Фенотипом, ассоциированным с тяжелым, трудно контролируемым течением заболевания, является БА с фиксированной обструкцией дыхательных путей (ФОДП). Высокий риск обострений, трудность достижения контроля и тяжесть астмы у таких больных обусловлены поражением периферических дыхательных путей. В связи с этим главная терапевтическая мишень при этом заболевании – дистальные отделы бронхиального дерева, и от степени депонирования в них лекарственного вещества зависит эффективность ингаляционной терапии. Экстрамелкодисперсная фиксированная комбинация беклометазона дипропионата, формотерола и гликопиррония бромида воздействует на воспаление в дистальных отделах бронхиального дерева и является приоритетной в лечении больных тяжелой БА с ФОДП, способствуя достижению контроля над заболеванием.

bronchial asthmafixed respiratory obstructionbeclomethasone dipropionateformoterolglycopyrronium bromidetriple therapyбронхиальная астмафиксированная обструкция дыхательных путейбеклометазон дипропионатформотеролгликопиррония бромидтройная терапияGlobal strategy for asthma management and prevention (GINA). 2021. URL: https://ginasthma.org/ (date of access – 29.10.2024).Авдеев С.Н., Ненашева Н.М., Жуденков К.В. с соавт. Распространенность, заболеваемость, фенотипы и другие характеристики тяжелой бронхиальной астмы в Российской Федерации. Пульмонология. 2018; 28(3): 341–358 [Avdeev S.N., Nenasheva N.M., Zhudenkov K.V. et al. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Pulmonologiya = Pulmonology. 2018; 28(3): 341–358 (In Russ.)]. https://doi.org/10.18093/0869-0189-2018-28-3-341-358. EDN: XWCRRZ.Cottini M., Licini A., Lombardi C. et al. Small airway dysfunction and poor asthma control: A dangerous liaison. Clin Mol Allergy. 2021; 19(1): 7. https://doi.org/10.1186/s12948-021-00147-8. PMID: 34051816. PMCID: PMC8164746.Bakakos A., Vogli S., Dimakou K., Hillas G. Asthma with fixed airflow obstruction: From fixed to personalized approach. J Pers Med. 2022; 12(3): 333. https://doi.org/10.3390/jpm12030333. PMID: 35330333. PMCID: PMC8953236.Bennett G.H., Carpenter L., Hao W. et al. Risk factors and clinical outcomes associated with fixed airflow obstruction in older adults with asthma. Ann Allergy Asthma Immunol. 2018; 120(2): 164–168.e1. https://doi.org/10.1016/j.anai.2017.10.004. PMID: 29290515. PMCID: PMC5803342.Крапошина А.Ю., Собко Е.А., Демко И.В. с соавт. Современные представления о бронхиальной астме с фиксированной обструкцией. Терапевтический архив. 2021; 93(3): 337–342. [Kraposhina A.Yu., Sobko E.A., Demko I.V. et al. Modern concepts of bronchial asthma with fixed obstruction. Terapevticheskiy arkhiv = Therapeutic Archive. 2021; 93(3): 337–342 (In Russ.)]. https://doi.org/10.26442/00403660.2021.03.200661. EDN: JXDXLL.Crisafulli Е., Zanini A., Pisi G. et al. Inhaled beclometasone dipropionate / formoterol fumarate extrafine fixed combination for the treatment of asthma. Expert Rev Respir Med. 2016; 10(5): 481–90. https://doi.org/10.1586/17476348.2016.1161508. PMID: 26938578.Díaz-García R., Flores-Ramírez G., Ramírez-Oseguera R.T. Effect of extrafine formulation of BDP/FF inhaler on asthma control, small airway function and airway inflammation among Mexican asthmatic patients. A retrospective analysis. Respir Med. 2020; 165: 105932. https://doi.org/10.1016/j.rmed.2020. PMID: 32308205.Casale Т.B., Foggs M.B., Balkissoon R.C. Optimizing asthma management: Role of long-acting muscarinic antagonists. J Allergy Clin Immunol. 2022; 150(3): 557–68. https://doi.org/10.1016/j.jaci.2022.06.015. PMID: 35933228.Cazzola М., Rogliani P., Matera M.G. Might it be appropriate to anticipate the use of long-acting muscarinic antagonists in asthma? Drugs. 2023; 83(11): 957–65. https://doi.org/10.1007/s40265-023-01897-2. PMID: 37303017. PMCID: PMC10322754.Haddad A., Gaudet M., Plesa M. et al. Neutrophils from severe asthmatic patients induce epithelial to mesenchymal transition in healthy bronchial epithelial cells. Respir Res. 2019; 20(1): 234. https://doi.org/10.1186/s12931-019-1186-8. PMID: 31665016. PMCID: PMC6819645.Rutting S., Tonga K.O., King G.G. Toward explaining fixed airflow obstruction in asthma. J Allergy Clin Immunol. 2022; 149(3): 890–92. https://doi.org/10.1016/j.jaci.2021.12.784. PMID: 34974066.Mogensen I., Alving K., Dahlen S.-E. et al. Fixed airflow obstruction relates to eosinophil activation in asthmatics. Clin Exp Allergy. 2019; 49(2): 155–62. https://doi.org/10.1111/cea.13302. PMID: 30365193.Domingo C., Palomares O., Sandham D.A. et al. The prostaglandin D2 receptor 2 pathway in asthma: A key player in airway inflammation. Respir Res. 2018; 19(1): 189. https://doi.org/10.1186/s12931-018-0893-x. PMID: 30268119. PMCID: PMC6162887.Takahashi K., Meguro K., Kawashima H. et al. Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. J Asthma. 2019; 56(3): 236–43. https://doi.org/10.1080/02770903.2018.1455855. PMID: 29648484.Федосеев Г.Б., Трофимов В.И., Негруца К.В. с соавт. ACOS – самостоятельная нозологическая форма? Клиническая картина и диагностика ACOS. Пульмонология. 2018; 28(5): 519–529. [Fedoseev G.B., Trofimov V.I., Negrutsa K.V. et al. Is ACOS an independent nosology? Clinical signs and diagnosis of ACOS. Pulmonologiya = Pulmonology. 2018; 28(5): 519–529 (In Russ.)]. https://doi.org/10.18093/0869-0189-2018-28-5-519-529. EDN: YXZXFB.Chipps B.E., Hirsch I., Trudo F. et al. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma. Ann Allergy Asthma Immunol. 2020; 124(1): 79–86. https://doi.org/10.1016/j.anai.2019.10.006. PMID: 31626906.Tonga K.O., Chapman D.G., Farah C.S. et al. Reduced lung elastic recoil and fixed airflow obstruction in asthma. Respirology. 2020; 25(6): 613–19. https://doi.org/10.1111/resp.13688. PMID: 31482693.Miravitlles M. Diagnosis of asthma – COPD overlap: The five commandments. Eur Respir J. 2017; 49(5): 1700506. https://doi.org/10.1183/13993003.00506-2017. PMID: 28461307.Овсянников Н.В., Билевич О.А., Зинченко Л.М. с соавт. Новые возможности достижения контроля над течением тяжелой бронхиальной астмы. Вестник современной клинической медицины. 2019; 12(4): 63–68 [Ovsyannikov N.V., Bilevich O.А., Zinchenko L.M. et al. New opportunities in achievement control over the course of severe bronchial asthma. Vestnik sovremennoy klinicheskoy meditsiny = The Bulletin of Contemporary Clinical Medicine. 2019; 12(4): 63–68 (In Russ.)]. https://doi.org/10.20969/VSKM.2019.12(4).63-68. EDN: FKWTYC.Katoh S., Ikeda M., Shirai R. et al. Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease. J Asthma. 2018; 55(10): 1052–58. https://doi.org/10.1080/02770903.2017.1391281. PMID: 29035604.Uzan G.C., Borekci S., Doventas Y.E. et al. The relationship between inflammatory markers and spirometric parameters in ACOS, Asthma, and COPD. J Asthma. 2020; 57(12): 1273–79. https://doi.org/10.1080/02770903.2019.1652644. PMID: 31403365.Rogliani P., Ora J., Puxeddu E., Cazzola M. Airflow obstruction: Is it asthma or is it COPD? Int J Chron Obstruct Pulmon Dis. 2016; 11: 3007–13. https://doi.org/10.2147/COPD.S54927. PMID: 27942210. PMCID: PMC5137932.Cottee A.M., Seccombe L.M., Thamrin C. et al. Oscillometry and asthma control in patients with and without fixed airflow obstruction. J Allergy Clin Immunol Pract. 2022; 10(5): 1260–1267.e1. https://doi.org/10.1016/j.jaip.2021.12.026. PMID: 34979333.Tashkin D.P., Moore G.E., Trudo F. et al. Assessment of consistency of fixed airflow obstruction status during budesonide/formoterol treatment and its effects on treatment outcomes in patients with asthma. J Allergy Clin Immunol Pract. 2016; 4(4): 705–12. https://doi.org/10.1016/j.jaip.2016.02.014. PMID: 27039236.Трофименко И.Н., Черняк Б.А. Экстрамелкодисперсная комбинация беклометазона дипропионата и формотерола в лечении обструктивных бронхолегочных заболеваний. Медицинский совет. 2020; (11): 108–115. [Trofimenko I.N., Chernyak B.A. The extra-fine combination of beclomethasone dipropionate and formoterol in the treatment of obstructive bronchopulmonary diseases. Meditsinskiy sovet = Medical Council. 2020; (11): 108–115 (In Russ.)]. https://doi.org/10.21518/2079-701X-2020-11-108-115. EDN: NCPSSB.Barnes P.J. Cellular and molecular mechanisms of asthma and COPD. Clin Sci (Lond). 2017; 131(13): 1541–58. https://doi.org/10.1042/CS20160487. PMID: 28659395.Carr T.F., Altisheh R., Zitt M. Small airways disease and severe asthma. World Allergy Organ J. 2017; 10(1): 20. https://doi.org/10.1186/s40413-017-0153-4. PMID: 28649293. PMCID: PMC5479008.Kim L.H.Y., Saleh C., Whalen-Browne A. et al. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: A systematic review and meta-analysis. JAMA. 2021; 325(24): 2466–79. https://doi.org/10.1001/jama.2021.7872. PMID: 34009257. PMCID: PMC8135065.Hsieh M.-J., Lin Y.-C., Lai R.-S. et al. Comparative efficacy and tolerability of beclomethasone/formoterol and fluticasone/salmeterol fixed combination in Taiwanese asthmatic patients. J Formos Med Assoc. 2018; 117(12): 1078–85. https://doi.org/10.1016/j.jfma.2017.12.005. PMID: 29292054.Клинические рекомендации. Бронхиальная астма. Российское респираторное общество, Российская ассоциация аллергологов и клинических иммунологов, Союз педиатров России. Рубрикатор клинических рекомендаций Минздрава России. 2021. ID: 359. Доступ: https://cr.minzdrav.gov.ru/schema/359_2 (дата обращения – 29.10.2024). [Clinical guidelines. Bronchial asthma. Russian Respiratory Society, Russian Association of Allergists and Clinical Immunologists, Union of Pediatricians of Russia. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2021. ID: 359. URL: https://cr.minzdrav.gov.ru/schema/359_2 (date of access – 29.10.2024) (In Russ.)].Carpagnano G.E., Portacci А., Dragonieri S. et al. Managing small airway disease in patients with severe asthma: Transitioning from the “silent zone” to achieving “quiet asthma”. J Clin Med. 2024; 13(8): 2320. https://doi.org/10.3390/jcm13082320. PMID: 38673593. PMCID: PMC11051485.Virchow J.C., Kuna P., Paggiaro P. et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): Two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019; 394(10210): 1737–49. https://doi.org/10.1016/S0140-6736(19)32215-9. PMID: 31582314.Agusti A., Fabbri L., Lahousse L. et al. Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. Allergy. 2022; 77(4): 1105–13. https://doi.org/10.1111/all.15076. PMID: 34478578. PMCID: PMC9290056.Kotoulas S.-C., Tsiouprou I., Domvri K. et al. Open and closed triple inhaler therapy in patients with uncontrolled asthma. Adv Respir Med. 2023; 91(4): 288–300. https://doi.org/10.3390/arm91040023. PMID: 37489386. PMCID: PMC10366885.The European Clinical Trials Register (EU-CTR). URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000716-18/results (date of access – 29.10.2024).The European Clinical Trials Register (EU-CTR V1.1). URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000717-40/results (date of access – 29.10.2024).Oba Y., Anwer S., Maduke T. et al. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: A systematic review and network meta-analysis. Cochrane Database Syst Rev. 2022; 12(12): CD013799. https://doi.org/10.1002/14651858.CD013799.pub2. PMID: 36472162. PMCID: PMC9723963.Papi A., Singh D., Virchow J.C. et al. Normalisation of airflow limitation in asthma: Post-hoc analyses of TRIMARAN and TRIGGER. Clin Transl Allergy. 2022; 12(4): e12145. https://doi.org/10.1002/clt2.12145. PMID: 35450196. PMCID: PMC9014197.